Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

49.24 +0.43 (+0.88%)
Official Closing Price Updated: 4:10 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
News headline image
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars ↗
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial... 
Via Benzinga
News headline image
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month ↗
GSK settles California lawsuits over Zantac cancer allegations. Confidential agreements reached, cases dismissed. 
Via Benzinga
Topics Lawsuit
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection ↗
Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising... 
Via Benzinga
News headline image
Looking Into GSK's Recent Short Interest ↗
 
Via Benzinga
News headline image
Recap: GSK Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For GSK ↗
 
Via Benzinga
News headline image
A Look Into GSK Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List ↗
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
News headline image
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report ↗
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
News headline image
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus ↗
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
News headline image
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth ↗
Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop. 
Via InvestorPlace
News headline image
Dividend Income Update January 2024 ↗
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio 
Via Talk Markets
News headline image
Why Is Moderna Stock Trading Lower Today? ↗
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer. 
Via Benzinga
News headline image
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally 
From Alector, Inc.
Via GlobeNewswire
News headline image
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 
From 23andMe, Inc.
Via GlobeNewswire
News headline image
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
News headline image
Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK). 
Via Benzinga
News headline image
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
News headline image
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option ↗
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024. 
Via Benzinga
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
What's Going On With GSK Stock Today? ↗
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency. 
Via Benzinga
Topics Lawsuit
News headline image
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
News headline image
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine ↗
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections. 
Via Benzinga
News headline image
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
News headline image
Earnings Scheduled For January 31, 2024 ↗
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
News headline image
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
News headline image
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.